格隆汇3月23日丨亚香股份(301220.SZ)在互动平台表示，公司国外客户主要包括国际香精香料公司 （IFF）、奇华顿（Givaudan）、芬美意（Firmenich）等国际知名香精香料企业。目前公司与巴斯夫公 司在供应链环节有业务合作关系。 ...

每经AI快讯，有投资者在投资者互动平台提问：请问公司国外客户有哪些，与巴斯夫有合作吗？ 亚香股份（301220.SZ）3月23日在投资者互动平台表示，公司国外客户主要包括国际香精香料公司 （IFF）、奇华顿（Givaudan）、芬美意（Firmenich）等国际知名香精香料企业。目前公司与巴斯夫公 司在供应链环节有业务合作关系。 （文章来源：每日经济新闻） ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 证券代码：301220 证券简称：亚香股份 公告编号：2026-006 昆山亚香香料股份有限公司 关于控股股东、实际控制人的一致行动人 提前终止减持计划暨减持结果的公告 控股股东、实际控制人的一致行动人周军芳保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 昆山亚香香料股份有限公司（以下简称"公司"）于 2026 年 1 月 9 日披露 了《关于控股股东、实际控制人的一致行动人减持股份预披露公告》（公告编号： 2026-001）。控股股东、实际控制人的一致行动人周军芳计划自减持计划披露之 日起 15 个交易日后的三个月内（自 2026 年 1 月 31 日至 2026 年 4 月 30 日，法 律法规、规范性文件规定不得进行减持的时间除外）以集中竞价和大宗交易方式 合计减持不超过 251,000 股（占公司总股本 0.22%）。 公司于近日收到周军芳出具的《关于提前终止减持计划暨减持结果的告知 函》，截至本公告披露日，周军芳本次已减持股份 230,000 股，其决定提前终止 本次股份减持计划，本次未完成减持的 ...

昆山亚香香料股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301220 证券简称：亚香股份 公告编号：2026-005 昆山亚香香料股份有限公司（以下简称"公司"）近日接到控股股东、实际控制 人周军学先生的通知，周军学先生将其所持有的部分公司股份进行了质押，具体事项 如下： | | 如下： | 昆山亚香香料股份有限公司（以下简称"公司"）近日接到控股股东、实际控制 人周军学先生的通知，周军学先生将其所持有的部分公司股份进行了质押，具体事项 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 一、股东股份质押基本情况 | | | | | | | | 质 质 押 权 用 人 途 | | 股东 | 是否为控股股东 | 本次质押数量 | 占其所持 | 占公司总 | 是否为限 售股 | 是否为补 | 质押起 | 质押到 | | | | 名称 | 或第一大股东及 | | 股 ...

Group 1 - The core point of the article is that Yaxiang Co., Ltd. (stock code: 301220) has over 9,300 shareholders as of February 10, 2026 [1]

（文章来源：证券日报） 证券日报网讯 2月24日，亚香股份在互动平台回答投资者提问时表示，截至2026年2月13日公司共有股 东9300余户。 ...

Investment Rating - The industry rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the rapid integration of biotechnology into economic and social development, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][4]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to enhance its R&D and production capabilities in the pharmaceutical and health sectors [32]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to reshape the plant protein market [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new funding rounds since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17]. Policy and Regulatory Developments - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards establishing a new green development framework [7]. - The National Health Commission approved 22 new food items, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) production [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand efforts in synthetic biology and related fields [9].

Group 1 - The company, Yaxiang Co., Ltd. (stock code: 301220), reported that as of January 30, 2026, it has over 9,400 shareholders [1]

Core Viewpoint - The company, Yaxiang Co., is currently in good operational condition and expects steady growth in sales due to the successful production launch of its Thai manufacturing base and increasing capacity since 2025 [2] Group 1: Operational Performance - The company is focused on enhancing internal management capabilities and performance levels [2] - Short-term profitability is significantly influenced by industry competition, domestic and international economic conditions, and changes in international trade policies [2] Group 2: Strategic Initiatives - The company aims to maintain long-term cooperative relationships with global clients [2] - Efforts are being made to improve operational management, reduce costs, and enhance efficiency [2] - The company is investing heavily in research and development of new technologies and expanding its product offerings [2]

Core Viewpoint - On February 4, Yaxiang Co., Ltd. executed a block trade of 1 million shares, amounting to 32.5 million yuan, which represented 43.46% of the total trading volume for the day, with a transaction price of 32.5 yuan, reflecting an 11.64% discount compared to the market closing price of 36.78 yuan [1][2]. Summary by Categories - **Transaction Details** - The block trade involved 1 million shares of Yaxiang Co., Ltd. at a price of 32.5 yuan per share [1][2]. - The total transaction value was 32.5 million yuan [1][2]. - This transaction accounted for 43.46% of the total trading volume on that day [1]. - **Price Comparison** - The transaction price of 32.5 yuan was 11.64% lower than the market closing price of 36.78 yuan [1].